Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
66 hedge funds and large institutions have $117M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 10 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 72 → 66 (-6)
18% less capital invested
Capital invested by funds: $143M → $117M (-$26M)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$2.02M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$1.26M |
| 3 |
SCM
Sio Capital Management
New York
|
+$1.01M |
| 4 |
SAM
Senzar Asset Management
New York
|
+$655K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$580K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
-$2.17M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$877K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$487K |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$437K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$404K |
FOMX Hedge Fund Activity: Q1 2016 in Review
66 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q1 2016, worth a combined $117M — down 18% from $143M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of FOMX and 4 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 27 added.
The largest buyer was Tekla Capital Management, adding an estimated $2.02M. The largest seller was Cadian Capital Management, exiting entirely with an estimated $2.17M sold.
- 66 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q1 2016, down from 72 in Q4 2015.
- Funds reported $117M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q1 2016, down 18% quarter-over-quarter.
- 4 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q1 2016 and 10 closed out, a net change of -6 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q1 2016 was Tekla Capital Management, an estimated $2.02M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q1 2016 was Cadian Capital Management, an estimated $2.17M sold.
Based on aggregated 13F filings for Q1 2016.